(1R,3S,4R)-4-((3AR,9BR)-9B-((4-FLUOROPHENYL)SULFONYL)-7-(PERFLUOROPROPAN-2-YL)-2,3,3A,4,5,9B-HEXAHYDRO-1H-BENZO(E)INDOLE-3-CARBONYL)-3-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID
Inflammatory Bowel Diseases
Bristol-Myers SquibbSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Inflammatory Bowel Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MACROGOLS Region Skane | Phase 4 | A |
Prucalopride Region Skane | Phase 4 | BBB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Cedars-Sinai Medical Center | Phase 4 | BBB |
Epinephrine Cedars-Sinai Medical Center | Phase 4 | BB |
DEXAMETHASONE Cedars-Sinai Medical Center | Phase 4 | BB |
View all 31 →
Same molecule, other indications
(1R,3S,4R)-4-((3AR,9BR)-9B-((4-FLUOROPHENYL)SULFONYL)-7-(PERFLUOROPROPAN-2-YL)-2,3,3A,4,5,9B-HEXAHYDRO-1H-BENZO(E)INDOLE-3-CARBONYL)-3-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →